Targeting STEAP1 Protein in Human Cancer : Current Trends and Future Challenges
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 18(2018), 3 vom: 08., Seite 222-230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barroca-Ferreira, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.04.2019 Date Revised 26.04.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009617666170427103732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271464291 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271464291 | ||
| 003 | DE-627 | ||
| 005 | 20231224232747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009617666170427103732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0904.xml |
| 035 | |a (DE-627)NLM271464291 | ||
| 035 | |a (NLM)28460619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barroca-Ferreira, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting STEAP1 Protein in Human Cancer |b Current Trends and Future Challenges |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2019 | ||
| 500 | |a Date Revised 26.04.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a DNA vaccines | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a STEAP1 | |
| 650 | 4 | |a Small noncoding RNA | |
| 650 | 4 | |a prostate cancer. | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Oxidoreductases |2 NLM | |
| 650 | 7 | |a EC 1.- |2 NLM | |
| 650 | 7 | |a STEAP1 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.16.1.- |2 NLM | |
| 700 | 1 | |a Pais, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Goncalves, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, I M |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, I |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Passarinha, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Maia, C J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 18(2018), 3 vom: 08., Seite 222-230 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:3 |g day:08 |g pages:222-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009617666170427103732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 3 |b 08 |h 222-230 | ||